 This is a multicenter phase II clinical study of trametinib in combination with GSK2141795 in patients with BRAF wild-type mutation melanoma. All patients will receive continuous dosing of trametinib 2 mg in combination with GSK2141795 25 mg oral daily until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity. Imaging CT or MRI will be performed within 7 days prior to day 1 of Odd Cycles, starting with Cycle 3. 